From the impact of Obamacare to cutting-edge research, biotech buyouts to Big Pharma court battles, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care and their implications for long-term investors. In this week's edition, the team talks about the biggest headlines, stocks that have both popped and dropped, and companies our analysts will be watching in the coming days.
In the following segment, health-care analyst David Williamson discusses the exciting news for seasonal allergy sufferers. Watch and find out how this brand-new drug is poised to help Merck, and investors, reap pollen profits.
What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: What's Really Eating At America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
The article The New Cure for Seasonal Allergies originally appeared on Fool.com.
Brenton Flynn, Max Macaluso, Ph.D., and David Williamson have no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.